Related Experiment Video

Updated: Aug 16, 2026

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts
06:32

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Published on: April 13, 2022

Integrity and stability of the citrulline-arginine pathway in normal and tumour cell lines

Denys N Wheatley1, Ruth Kilfeather, Alison Stitt

  • 1BioMedES, Hilton Campus, Hilton Place, Aberdeen AB24 4FA, UK. wheatley@abdn.ac.uk

Cancer Letters
|August 23, 2005
PubMed

Insights

Arginine deprivation therapy shows promise for treating cancers like melanomas and hepatocellular carcinomas (HCC) by selectively targeting tumor cells unable to recycle arginine. This approach is moving into clinical trials, offering new treatment strategies.

Area of Science:

  • Oncology
  • Biochemistry
  • Cancer Therapy

Background:

  • Arginine catabolizing enzymes have a long history in cancer treatment.
  • Recent research has reinvestigated their ability to inhibit proliferation and induce tumor cell death.

Purpose of the Study:

  • To explore the potential of arginine deprivation as a cancer treatment strategy.
  • To investigate the selectivity of arginine deprivation based on urea cycle enzyme activity in tumor cells.

Main Methods:

  • Analysis of urea cycle enzyme activity in various normal and malignant cell lines.
  • Assessment of arginine recycling precursor pathways in different tumor types.
  • Evaluation of arginine deprivation protocols in preclinical and early clinical settings.

Main Results:

  • Many tumors, including melanomas and hepatocellular carcinomas (HCC), exhibit poor ability to circumvent arginine deprivation via the urea cycle.
  • Urea cycle enzyme deficiency varies across tumor types, but enzyme activity is generally stable in both normal and tumor cells.
  • Early clinical findings suggest encouraging results for arginine deprivation therapy.

Conclusions:

  • Arginine deprivation presents a viable therapeutic window for specific cancers, particularly those with impaired urea cycle function.
  • This approach is advancing into clinical application for melanomas, HCCs, and leukemias.
  • Arginine deprivation can be a valuable component of combination therapy, potentially sensitizing tumor cells for enhanced treatment outcomes.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Viability Assays for Cells in Culture12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Urea Cycle01:23

Urea Cycle

The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.